Get the Stockscreener App
9.19
2.91%
0.26
After Hours:
9.19
Kamada Ltd stock is traded at $9.19, with a volume of 92,847.
It is up +2.91% in the last 24 hours and up +13.46% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$8.93
Open:
$9.1
24h Volume:
92,847
Relative Volume:
1.13
Market Cap:
$530.09M
Revenue:
$154.57M
Net Income/Loss:
$15.07M
P/E Ratio:
34.04
EPS:
0.27
Net Cash Flow:
$10.92M
1W Performance:
-1.29%
1M Performance:
+13.46%
6M Performance:
+30.17%
1Y Performance:
+39.03%
1-Day Range:
$9.002
$9.24
1-Week Range:
$8.62
$9.24
52-Week Range:
$5.54
$9.35
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
9.19 | 515.10M | 154.57M | 15.07M | 10.92M | 0.27 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | The Benchmark Company | Buy |
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Kamada Sets March 11, 2026 Date to Report Fiscal 2025 Results - TipRanks
Kamada schedules release of fiscal year and Q4 2025 results for March 11 - Investing.com
Kamada (NASDAQ: KMDA) schedules March 11 call on 2025 results - Stock Titan
Rare-disease drugmaker Kamada to detail 2025 results on March 11 - Stock Titan
Setup Watch: Can Kamada Ltd disrupt its industryJuly 2025 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Kamada Ltd. (KMDA) Stock Analysis: Unveiling a 45.9% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Kamada Ltd expected to post earnings of 8 cents a shareEarnings Preview - TradingView
Kamada (KMDA) Projected to Post Earnings on Wednesday - MarketBeat
Kamada (NASDAQ:KMDA) Reaches New 12-Month HighStill a Buy? - MarketBeat
Market Leaders: Can Kamada Ltd generate free cash flowTrade Ideas & Short-Term High Return Strategies - baoquankhu1.vn
Can Kamada Ltd. generate free cash flowWeekly Market Summary & Detailed Earnings Play Strategies - mfd.ru
Can Kamada Ltd. outperform in the next rallyTreasury Yields & Advanced Swing Trade Entry Plans - mfd.ru
Kamada Ltd. (KMDA) Stock Analysis: Exploring A 50% Upside Potential - DirectorsTalk Interviews
Kamada (NASDAQ:KMDA) Sets New 52-Week HighStill a Buy? - MarketBeat
Are Investors Undervaluing Kamada (KMDA) Right Now? - Yahoo Finance
Will Kamada Ltd. stock reach all time highs in 2025Short Setup & Entry Point Confirmation Signals - mfd.ru
Can Kamada Ltd. disrupt its industryJuly 2025 Chart Watch & Free Verified High Yield Trade Plans - mfd.ru
Is Kamada Ltd. stock a buy or sellJuly 2025 Spike Watch & High Accuracy Swing Entry Alerts - mfd.ru
Kamada Ltd. (KMDA) Stock Analysis: Unveiling a 51.69% Potential Upside in Healthcare Investments - DirectorsTalk Interviews
Will Kamada Ltd. stock gain from government policiesWall Street Watch & Risk Managed Investment Entry Signals - mfd.ru
Weekly Earnings: Is Kamada Ltd stock a buy or sellWeekly Earnings Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Is Kamada Ltd. exposed to political riskTrade Exit Summary & Growth Oriented Trading Recommendations - mfd.ru
Does Kamada Ltd. stock trade at a discount to peersEarnings Overview Summary & Pattern Based Trade Signal System - mfd.ru
Sentiment Review: Is Kamada Ltd exposed to political riskCEO Change & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Is Kamada Ltd exposed to political riskWeekly Trading Summary & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Intraday: Can Kamada Ltd navigate macro headwindsPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Kamada (TLV:KMDA) shareholder returns have been favorable, earning 74% in 3 years - simplywall.st
Can Kamada Ltd. continue delivering strong returnsJuly 2025 Gainers & Verified Chart Pattern Signals - mfd.ru
Pharma News: Will Kamada Ltd outperform the market in YEAR2025 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Volume Summary: Is Kamada Ltd a potential multi baggerTrade Entry Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Kamada Ltd. (KMDA) Stock Analysis: Exploring a 62.91% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Kamada Ltd: Biopharma under Pressure as KMDA Stock Tests Investor Patience - AD HOC NEWS
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - openPR.com
Is Kamada Ltd. stock a safe investment in uncertain marketsSector ETF Performance & Fast Growing Trading Plans - Bollywood Helpline
Kamada Ltd. (KMDA) Stock Analysis: Exploring A 58.15% Upside In The Healthcare Space - DirectorsTalk Interviews
Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio | Corporate - EQS News
Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio - NewMediaWire
Kamada Projects Strong 2026 Growth Fueled by Plasma Portfolio and Distribution Expansion - citybuzz -
Kamada shares climb after upbeat 2026 outlook points to double-digit growth - MSN
HC Wainwright Issues Optimistic Forecast for Kamada Earnings - Defense World
Kamada shares drop as company halts Phase 3 study of inhaled AAT therapy - MSN
Q1 Earnings Forecast for Kamada Issued By HC Wainwright - Defense World
Kamada Ltd. (KMDA) Stock Analysis: Unpacking a 63.52% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Q1 Earnings Estimate for Kamada Issued By HC Wainwright - MarketBeat
Can Kamada Ltd. stock attract ESG capital inflowsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - Улправда
Benchmark reiterates Buy rating on Kamada stock, maintains $15 target By Investing.com - Investing.com Nigeria
Benchmark reiterates Buy rating on Kamada stock, maintains $15 target - Investing.com
Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers (NASDAQ:KMDA) - Seeking Alpha
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):